Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced it will release its fourth-quarter 2025 financial results after the market closes on Thursday, February 26, 2026. The company will host a conference call on the same day at 2:00 PM Pacific Time to discuss these results. Interested parties can access the call via a toll-free number or the Investors page on Amphastar's website, with a webcast replay available within 24 hours.
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Navigating a 10.78% Upside Potential
Amphastar Pharmaceuticals, Inc. (AMPH) shows a promising outlook with a potential upside of 10.78% from its current trading price of $28.50, according to analyst ratings. The company, which specializes in specialty and generic drug manufacturing, boasts a strong financial position with a forward P/E ratio of 8.08, robust free cash flow, and an impressive return on equity. Its diverse product portfolio and strategic focus on key healthcare sectors suggest continued growth in the evolving pharmaceutical landscape.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Hold" from Analysts
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has received an average "Hold" recommendation from eight analysts, with six recommending "Hold" and two "Buy," and an average one-year target price of $31.00. Recent analyst downgrades and price target cuts have come from Zacks, Needham, and Barclays. Insider selling, including significant sales by a Director and an EVP, totals 18,129 shares worth approximately $477,176 in the last 90 days, with insiders still owning 27.10% of the stock.
Hypoglycemia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Amphastar Pharma, Eiger BioPharma, Eli Lilly, Novo Nordisk, Xeris Pharma
DelveInsight's "Hypoglycemia Pipeline Insight, 2025" report outlines the current clinical development landscape for hypoglycemia, identifying over 10 companies working on 12+ treatment therapies. The report details pipeline products from pre-clinical to marketed phases, including their mechanisms of action, clinical study status, and product development activities. Key companies mentioned include Twist Bioscience, Eiger BioPharmaceuticals, Eli Lilly, and Novo Nordisk, with therapies like Avexitide and MBX 1416 progressing through clinical trials.
Denali Advisors LLC Buys New Stake in Amphastar Pharmaceuticals, Inc. $AMPH
Denali Advisors LLC has acquired a new position of 135,000 shares in Amphastar Pharmaceuticals (NASDAQ:AMPH) during the third quarter, valued at approximately $3.6 million. This move is part of broader institutional interest, with other firms like Qube Research & Technologies and Geode Capital Management also increasing their stakes. Despite these acquisitions, analysts maintain a "Hold" consensus rating with a target price of $31.00, reflecting mixed views on the stock.
Do options traders know something about Amphastar Pharmaceuticals stock we don't?
This article analyzes unusual options activity for Amphastar Pharmaceuticals (AMPH), revealing a significant bullish sentiment among large investors. Despite the stock trading near all-time highs, this activity suggests that sophisticated traders anticipate further upside for AMPH. The analysis delves into specific put and call option trades, price targets, and the potential implications for the stock's future performance.
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
Amphastar Pharmaceuticals, Novavax, and Organon saw their shares jump significantly following a softer-than-expected January Consumer Price Index report, which has increased hopes for earlier interest rate cuts by the Federal Reserve. This positive inflation data led to a market rally, with Amphastar Pharmaceuticals rising 4.7%, Novavax 4.2%, and Organon 4.6%. The article highlights that lower inflation is crucial for the Fed to ease monetary policy, generally boosting stock valuations.
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
Amphastar Pharmaceuticals, Novavax, and Organon experienced a jump in their share prices following a softer-than-expected January Consumer Price Index (CPI) report. This inflation data has increased market hopes for interest rate cuts by the Federal Reserve as early as June, generally supporting stock valuations. The article also provides a deeper look into Amphastar Pharmaceuticals' recent stock performance and previous analyst outlooks.
Do Options Traders Know Something About Amphastar Pharmaceuticals Stock We Don't?
Options traders are showing significant interest in Amphastar Pharmaceuticals (AMPH) stock, particularly regarding a put option expiring in March 2026, indicating an expectation of a large price movement. Despite this, analysts currently rate AMPH as a Zacks Rank #3 (Hold), with no recent changes to earnings estimates. This high implied volatility could suggest a potential trading opportunity for those looking to sell premium, betting the stock won't move as drastically as implied.
How (AMPH) Movements Inform Risk Allocation Models
The article analyzes Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH), indicating a neutral near-term sentiment despite strong mid-term sentiment potentially stalling. It details AI-generated trading strategies for different risk profiles, including long, breakout, and short positions with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by New York State Common Retirement Fund
The New York State Common Retirement Fund increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 86.4% in the third quarter, acquiring an additional 41,800 shares to hold a total of 90,169 shares valued at approximately $2.40 million. Despite this institutional buying, company insiders have been net sellers, disposing of 34,808 shares worth $919,002 in the last three months. Analysts currently have an average "Hold" rating and a $31.00 price target for the stock, with Amphastar recently beating Q3 EPS estimates.
Is Amphastar (AMPH) Turning Margin Compression Into a Test of Its Operational Discipline?
Amphastar Pharmaceuticals Inc. recently experienced a 4.3 percentage point contraction in its adjusted operating margin due to rising expenses outpacing revenue, which is significant for a company with a smaller revenue base. This margin pressure, coupled with a high debt load, highlights challenges for the drugmaker, particularly concerning cost control and operational efficiency. Despite recent stock gains, there are varied investor opinions on its fair value, emphasizing the need for thorough analysis beyond herd mentality for potential investors.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Cross Above 50-Day Moving Average - Here's Why
Amphastar Pharmaceuticals (NASDAQ:AMPH) recently saw its shares cross above the 50-day moving average, trading as high as $29.37 and closing at $28.61. This technical breakout follows a period where analysts have given the stock a "Hold" consensus rating with an average price target of $31.00. The company reported strong financial results with an earnings beat, showcasing revenue of $191.84 million against estimates of $186.90 million.
SummerHaven Investment Management LLC Takes $1.02 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH
SummerHaven Investment Management LLC has acquired a new stake of 38,200 shares, valued at approximately $1.02 million, in Amphastar Pharmaceuticals, Inc. The investment represents about 0.08% of the company. Amphastar Pharmaceuticals recently reported strong Q3 earnings, exceeding analyst estimates with an EPS of $0.93 and revenue of $191.8 million, though insiders have been net sellers in recent months.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Hold" from Analysts
Amphastar Pharmaceuticals (NASDAQ: AMPH) has received an average "Hold" recommendation from eight analysts, with a mean 1-year price target of $31.00. Despite recent insider selling of over 35,000 shares, insiders still own 27.5% of the company. The company recently beat earnings expectations with EPS of $0.93 and revenue of $191.8 million, trading at a market cap of approximately $1.2 billion and a P/E ratio of ~11.6.
How Amphastar Pharmaceuticals Inc. (AMPH) Affects Rotational Strategy Timing
This article analyzes Amphastar Pharmaceuticals Inc. (AMPH) using AI models to provide insights into its stock performance and rotational strategy timing. It identifies a near-term weak sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 15.7% gain. The piece also outlines three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored to different risk profiles and holding periods, alongside multi-timeframe signal analysis.
Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock?
The options market is showing high implied volatility for Amphastar Pharmaceuticals (AMPH), particularly with the June 20, 2025 $65 Call, suggesting investors expect a significant price movement. Despite this, analysts currently rate Amphastar as a Zacks Rank #3 (Hold), with recent earnings estimates seeing a slight decline. This scenario could present a unique trading opportunity for options strategies focusing on premium selling.
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving
Amphastar Pharmaceuticals (AMPH) stock fell 5.3% after a Bank of America analyst lowered its price target and reports highlighted significant challenges in the company's product portfolio. Increased competition for its iron sucrose and glucagon products is expected to lead to lower sales and a moderated growth outlook. This decline follows a previous 4% drop, despite a recent agreement for a new drug compound that had temporarily boosted the stock.
A Look At Amphastar Pharmaceuticals (AMPH) Valuation After The AMP-110 License Agreement With Nanjing Hanxin
Amphastar Pharmaceuticals (AMPH) has gained attention after licensing AMP-110 for inflammatory and autoimmune diseases. Despite a recent share price jump, longer-term holders haven't seen a full recovery. Analysts generally view AMPH as undervalued, with a consensus price target of $32.0, suggesting a potential opportunity for investors.
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving
Shares of Amphastar Pharmaceuticals (AMPH) fell 5.3% after a Bank of America analyst lowered the price target due to expected significant challenges in the company's product portfolio. Increased competition for iron sucrose and glucagon products is anticipated to lead to lower sales, moderating the company's growth outlook from double-digit to high-single to low-double digits. This recent drop follows a previous 4% decline, indicating continued investor concern despite a recent licensing agreement for a new drug compound.
Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth
Amphastar Pharmaceuticals is strategically shifting its focus from generic drugs to higher-value proprietary products, aiming for a 50% proprietary mix by 2026. The company plans to launch AMP-007, a metered-dose inhaler, in mid-2026 as potentially the first generic in its market, and biosimilar insulin aspart (AMP-004) in 2027. Additionally, the recent acquisition of Baqsimi is expected to be transformative, with projected peak sales of $250-$275 million and mid-single-digit growth this year, alongside high single-digit growth for Primatene Mist.
2 Reasons to Avoid AMPH and 1 Stock to Buy Instead
This article advises investors to avoid Amphastar Pharmaceuticals (AMPH) despite its recent stock performance, citing two main reasons: limited distribution channels due to its smaller size in a scale-driven industry, and a shrinking adjusted operating margin over the past two years. The author suggests that while the valuation is reasonable, the company's shaky fundamentals present too much downside risk. Instead, the article recommends exploring other high-quality stock picks, particularly in the semiconductor sector.
Amphastar licenses synthetic ACTH analog for inflammatory conditions
Amphastar Pharmaceuticals has secured an exclusive license from Nanjing Hanxin Pharmaceutical Technology for AMP-110, a synthetic ACTH analog, for the U.S. and Canadian markets. This agreement involves an upfront payment of $2 million, with potential milestones up to $89 million and capped annual royalties. AMP-110 is aimed at treating inflammatory and autoimmune conditions, potentially offering an improved safety profile compared to existing treatments.
Is Amphastar Pharmaceuticals (AMPH) Attractively Priced After Recent Share Price Weakness?
Amphastar Pharmaceuticals (AMPH) appears attractively priced according to two valuation methods. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 69.7%, trading at US$27.74 against an estimated intrinsic value of US$91.66 per share. Additionally, its current P/E ratio of 11.4x is below both the industry average and Simply Wall St’s Fair Ratio, indicating it is undervalued based on earnings multiples.
Amphastar Pharmaceuticals Signs Multiple Material Agreements
Amphastar Pharmaceuticals (AMPH) has announced several agreements with affiliates of Hanxin and Genreach. These include an exclusive license for corticotropin products in the U.S. and Canada, an amendment to a distribution pact to cover Middle East and Southeast Asian countries, and an updated manufacturing agreement to expand global territories. The company stated these amendments are not expected to materially affect its financial condition.
Amphastar Licenses ACTH Analog AMP-110 for North America
Amphastar Pharmaceuticals has licensed AMP-110, an ACTH analog, for North America, paying a $2 million upfront fee to Nanjing Hanxin Pharmaceutical Technology. The deal includes significant milestone payments and royalties, positioning Amphastar in the growing U.S. ACTH market, which exceeded $684 million in 2024. Analysts currently rate AMPH stock as a Hold with a $30.00 price target, while TipRanks' AI Analyst, Spark, rates it as Outperform due to strong financial performance and strategic growth initiatives.
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
Amphastar Pharmaceuticals (AMPH) stock rose 5.8% after announcing an exclusive licensing agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for a new drug compound, AMP-110. This compound is intended to treat inflammatory and autoimmune conditions, with potential for improved safety. The deal includes an upfront payment of $2 million and potential future payments totaling up to $89 million.
Amphastar licenses synthetic ACTH analog for inflammatory conditions By Investing.com
Amphastar Pharmaceuticals, Inc. has entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for AMP-110, a synthetic ACTH analog for inflammatory and autoimmune conditions in the U.S. and Canada. The deal involves an upfront payment of $2 million, with potential milestones up to $89 million. This move strategically expands Amphastar's peptide portfolio, targeting a U.S. ACTH market that exceeded $684 million in 2024.
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
Amphastar Pharmaceuticals, Inc. has announced an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for the development and commercialization of AMP-110, a fully synthetic corticotropin compound, in the US and Canada. This agreement expands Amphastar's proprietary peptide pipeline to address inflammatory and autoimmune conditions, with AMP-110 offering a potentially improved safety profile over existing products. Amphastar made an upfront payment of $2 million, with potential for up to $14 million in development milestones and $75 million in sales milestones, along with royalty payments.
New synthetic hormone treatment targets autoimmune and inflammatory conditions
Amphastar Pharmaceuticals (AMPH) has licensed AMP-110, a fully synthetic human ACTH analog, from Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for development and commercialization in the U.S. and Canada. This drug targets inflammatory and autoimmune conditions and aims for an improved safety profile. The agreement includes an upfront payment, potential development and sales milestones, and capped royalty payments, positioning Amphastar to enter a U.S. ACTH market valued over $684 million annually.
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
Amphastar Pharmaceuticals has entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology for the development and commercialization of a fully synthetic corticotropin compound, AMP-110, in the U.S. and Canada. This agreement, which includes an upfront payment and potential milestone and royalty payments, expands Amphastar's peptide pipeline into inflammatory and autoimmune conditions. AMP-110 is currently in early-phase human clinical development and aims to offer an improved safety profile compared to existing treatments in a U.S. ACTH market valued over $684 million annually.
Amphastar Pharmaceuticals, Inc. $AMPH Stock Holdings Trimmed by CX Institutional
CX Institutional significantly reduced its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 76% in Q3 2025, selling 199,967 shares and retaining 63,316 shares valued at $1.69 million. Other institutional investors showed mixed activity, while company insiders, including EVP Rong Zhou and Director Richard K. Prins, were net sellers, offloading 35,308 shares totaling $931,637 in the last 90 days. Analysts maintain a "Hold" rating with an average target price of $31, despite the company recently surpassing Q3 earnings estimates.
Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Momentum
Amphastar Pharmaceuticals (AMPH) has shown recent short-term share price momentum, with a 3.4% rise over the past week, although its five-year return is mixed. Despite rising R&D and capital expenditures impacting profitability, a common valuation narrative suggests AMPH is 13.7% undervalued with a fair value of $32 compared to its current price of $27.62. The article encourages investors to conduct further research, noting potential for a stronger pipeline or faster product uptake to support higher earnings.
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that CEO Jack Zhang and CFO Bill Peters will present at the J.P. Morgan 2026 Healthcare Conference on January 14th, 2026, at 2:15 pm PT. The company, which specializes in developing and marketing generic and proprietary injectable, inhalation, and intranasal products, will make a webcast of the presentation available on its investor relations website for 30 days.
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that CEO Jack Zhang and CFO Bill Peters will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14th, 2026, at 2:15 pm PT. A webcast of the presentation will be available for 30 days on Amphastar's website. The company specializes in developing, manufacturing, and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced that CEO and President Jack Zhang and CFO Bill Peters will be presenting at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026, at 2:15 pm PT. The biopharmaceutical company specializes in developing, manufacturing, marketing, and selling complex generic and proprietary injectable, inhalation, and intranasal products. A webcast of the presentation will be available for 30 days on Amphastar's investor relations website.
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced that its CEO, Jack Zhang, and CFO, Bill Peters, will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026, at 2:15 pm PT. A webcast of the presentation will be available for 30 days on the company's investor relations website. Amphastar is a biopharmaceutical company focused on developing, manufacturing, marketing, and selling complex generic and proprietary injectable, inhalation, and intranasal products.
Responsive Playbooks and the AMPH Inflection
This article provides a comprehensive analysis of Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH), highlighting a mid-channel oscillation pattern and a significant risk-reward short setup. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report suggests that while short-term and mid-term signals are neutral, a long-term weak bias may be easing.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages
Eight brokerages currently cover Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), with a consensus "Hold" rating and an average 12-month price target of $31.00. The company recently reported better-than-expected quarterly earnings and revenue, with its stock trading around $27.12. Insider transactions indicate recent selling activity, while institutional investors hold a significant portion of the company's shares.
129,339 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC recently acquired a new position in Amphastar Pharmaceuticals, Inc., purchasing 129,339 shares valued at approximately $3.45 million, representing 0.28% ownership. This move comes as other institutional investors have also adjusted their holdings in the company. Analysts currently rate Amphastar as a "Hold" with an average target price of $31.00, while recent insider transactions show sales of approximately 35,808 shares.
How Investors Are Reacting To Amphastar Pharmaceuticals (AMPH) Teriparatide Pen Approval And Insider Stock Sale
Amphastar Pharmaceuticals recently received FDA approval for its teriparatide injection prefilled pen, coinciding with a director's stock sale following option exercise. This approval is seen as a helpful, but not transformational, catalyst for the company's growth, which also operates an ongoing share repurchase program. Investors are weighing the potential benefits of the new product against recent profit margin compression and earnings declines.
Squarepoint Ops LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH
Squarepoint Ops LLC significantly reduced its stake in Amphastar Pharmaceuticals by 67% in Q2, selling 46,744 shares. Despite this, Amphastar exceeded quarterly earnings expectations, and analysts maintain a consensus "Hold" rating with an average target price of $31.00. Insider selling has also been noted, with 35,808 shares sold in the last 90 days, though insiders still collectively own 27.5% of the company's stock.
A Fresh Look at Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Stabilisation
Amphastar Pharmaceuticals (AMPH) has seen its share price stabilize and bounce about 3% over the past week and 5% over the past month, despite being down sharply year-to-date. Analysts have a consensus price target of $32.0, suggesting the stock may be undervalued at its current trading price of $27.32. The article indicates that while the stock has pulled back, its modest growth and potential for higher margins from its expanding U.S. manufacturing and proprietary pipeline could present an opportunity.
Can Amphastar’s Recent Rebound Signal a Compelling Opportunity in 2025?
Amphastar Pharmaceuticals (AMPH) has seen a recent rebound, with its stock up 5.3% in the last week, even after significant year-to-date and annual declines. Despite volatility from pipeline updates and regulatory developments, the company scores as undervalued on valuation checks. Both Discounted Cash Flow and Price-to-Earnings analyses suggest the stock is significantly undervalued, presenting a potential opportunity for investors in 2025.
Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells 9,787 Shares of Stock
Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Rong Zhou sold 9,787 shares of company stock on December 17th, equating to a transaction value of $256,419.40 and reducing their stake by 6.62%. This sale occurred after the company recently surpassed quarterly earnings estimates. The stock currently holds a consensus "Hold" rating from analysts with an average price target of $31.00.
Insider Selling: Floyd Petersen Sells Shares of Amphastar Pharma
Floyd Petersen, a Director at Amphastar Pharmaceuticals Inc (AMPH), sold 4,163 shares of the company on December 12, 2025. This transaction leaves him with 71,368 shares. The stock is currently trading at $25.82, and GuruFocus estimates it to be significantly undervalued with a price-to-GF-Value ratio of 0.5.
Is FDA‑Cleared U.S.‑Made Teriparatide Pen Altering The Investment Case For Amphastar Pharmaceuticals (AMPH)?
Amphastar Pharmaceuticals recently gained FDA approval for a U.S.-made teriparatide injection pen, potentially transforming its investment profile from a generics focus to complex injectables and branded products. This move, targeting a US$585 million market, emphasizes domestic production and supply chain resilience. The success of this launch will be crucial in determining if the company can improve profitability and reduce reliance on older products, especially given recent earnings compression despite stable revenue.
Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Its Recent Share Price Slide
Amphastar Pharmaceuticals (AMPH) has experienced a significant share price downtrend over the last three months, prompting investors to question if the selloff is overextended. Despite modest revenue and earnings growth, the stock is sharply negative year-to-date. Analysts have a consensus price target of $32.0, suggesting the stock may be undervalued, although there is disagreement in price targets ranging from $25.0 to $38.0.
Amphastar: Baqsimi Props Up Flat Growth, But 2026 Guidance Looks Fragile (NASDAQ:AMPH)
Amphastar Pharmaceuticals (AMPH) is currently rated as a Hold due to concerns about flat revenue growth driven by reliance on BAQSIMI and PRIMATENE, declining legacy generics, and slipping gross margins. The company's 2026 guidance, projecting high single-digit to low double-digit growth, appears fragile, dependent on uncertain pipeline launches and impending patent expirations. Amphastar's slow transition to branded assets and the high clinical and regulatory risks associated with its pipeline further cloud its future outlook.
Is FDA‑Cleared U.S.‑Made Teriparatide Pen Altering The Investment Case For Amphastar Pharmaceuticals (AMPH)?
Amphastar Pharmaceuticals recently secured FDA approval for its U.S.-made teriparatide injection prefilled pen, a generic equivalent to Eli Lilly’s FORTEO, targeting a US$585 million market. This move underscores the company's shift towards higher-value products and domestic production, which could be critical for its profitability amidst recent earnings pressure. The success of this launch will test Amphastar's ability to leverage expanding domestic capacity to improve financial performance and reduce reliance on older offerings.
